Citi has initiated coverage on medical products firm ConvaTec Group PLC (LON:CTEC) with a ‘neutral’ rating and 138p target price as it thinks it is too early to buy the stock currently.
In a note to clients, the US investment bank’s analysts pointed out that ConvaTec is the cheapest MedTech stock in its universe although it operates in “structurally attractive markets and has a solid turnaround plan.”
READ: ConvaTec appoints Genus boss as chief executive to lead turnaround
However, they added: “We are awaiting evidence of improved execution and clarity on reinvestment to get more constructive on the shares.”
The analysts pointed out that its deep-dive analysis, work on Danish peer Coloplast and discussions with industry executives suggest that ConvaTec may have to reinvest more than it has announced, with another potential cost reset after the new CEO joins.
They added: “There is also a risk that turnaround may take longer than expected, given past execution issues.”
In early afternoon trading, ConvaTec shares were 0.3% higher at 136.70p.